Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Kedrion Biopharma expands its commitment in Turkey
Expansion plans revealed at Embassy reception in Ankara on October 14
4ID – Kedrion proud to support new App for patients with Immunodeficiencies
Our company restates its long-standing and consistent collaboration with IPOPI
Kedrion supports Italian liver transplantology
The company supported the Italian National Continuing Medical Education Program (ECM) event organized by Epateam aimed at specialists in the field
KIDCARES10, First Patient Treated in Pediatric PI Study
Thirty patients aged 2 to 17yo to be enrolled over five European countries
Kedrion stronger in North America and further committed to rare diseases
Agreement with Canadian-based Liminal BioSciences signed on June 22nd
World Blood Donor Day 2021, Kedrion pays tribute to the world of donors
A special edition for Italy, which is hosting the global World Blood Donor Day event
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
Kedrion supports World Primary Immunodeficiency Week
Early diagnosis and access to treatment to improve the quality of life of patients
Kedrion-Kamada, Anti-COVID IG development update
Watch the interview given to LeFontiTV by the CEO of our partner Kamada
